News
Curaxys, The New Spanish Biopharmaceutical Company Pioneer On
Biopharmaceuticals Biosimilars
By
Curaxys -
26 November 2009
Curaxys is the new company specialized in
the production of biosimilars medicines. It is an independent private
company, located on the technological park of Cadiz Spain). The new
venture is focuses in the development of new technological platforms.
(1888PressRelease)
November 26, 2009
- Curaxys is a biotechnology company that researches, develops, produces and
marketing biosimilars products using new biotechnology process and offering
to the market, high quality product at reasonable prices for the diseases
treatment.
Technologies:
It is remarkable to inform that in the last 20 years have demonstrated that
the baculoviruses maintains a reputation for producing high yields of
recombinant proteins in insect cells. Despite the difficulties of working
with a virus in eukaryotic cells, the fact that posttranslational
modifications such as glycosylation, fatty acid acylacion , disulfide bond
formation, and phosphorylation are carried out very similar to the same
process in mammalian cells, demonstrating the value of bacuviruses as
expression vectors.
We offer a complete range of biopharmaceuticals biosimilars with structure,
recombinant protein and monoclonal antibody.
The products are focused to improve the quality of life of patient with new
concept of product at reasonable cost in the field of the immunology, cancer
treatment, multiple sclerosis, and virology.
The productscurrently in pharmaceutical developement are:
Recombinants proteins:
1. Insulin
2. Growth Hormone
3. Erythropoietin
4. Granulocyte Colony Stimulating Factor ( GCSF)
Monoclonal Antibodies:
1. Rituximab
2. Trastuzumab
The founder and CEO and of the company is Dr. Manuel Esteban, PhD, MSc,
MBA,. He has over three decades of experience in pharmaceutical and
biopharmaceutical research conducted at leading pharmaceutical companies
such as Juste SAQF, Sanofi-Aventis, DSM Pharmaceuticals and Antibioticos (Montedison).
Dr. Esteban has held a variety of research management roles in projects
related to cell and microorganism culture, technological development, as
well as chemical, biochemical and enzymatic technologies. He is also a
proven business manager with the ability to bring in new clients, to create
new companies and to develop business opportunities.